What Is The Survival Rate Of Leiomyosarcoma?
Leiomyosarcoma is a malignant tumor of muscle cells that can appear in any part of the body, in which this type of tissue exists. However, the most frequent locations include the uterus, gastrointestinal tract and large vessels. In general, these neoplasms are classified as uterine and non-uterine (or soft tissue). The first ones represent approximately 1% of gynecological tumors and less than 5% of cancers of the uterine body.
Healthcare professionals usually use Leiomyosarcoma survival rates to debate a person’s prognosis in a standard way.
The 5-year survival rate of Leiomyosarcoma means the percentage of patients who live at least 5 years after being diagnosed with cancer. However, many patients of Leiomyosarcoma live much longer than 5 years (and many of them are cured).
Five-year relative survival rates estimate that some people will die from other causes and compare the observed survival with the expected in people without cancer. This allows us to better see the effect that cancer has on survival.
In order to obtain 5-year survival rates for Leiomyosarcoma, physicians have to observe people who received treatment at least 5 years ago. If treatment has enhanced since then, people who are now being diagnosed with soft tissue sarcoma may have a better prognosis.
Survival rates for leiomyosarcoma are usually based on previous results of a large number of people who had the disease; however, they cannot predict what will happen in a particular person’s case. Some factors may alter a person’s prognosis, such as the type of sarcoma, the location of the tumor, the treatment received, and the age of the patient. For example, sarcomas located in the arms or legs have a better outcome than those located elsewhere. In addition, elderly patients tend to have a worse survival rate compared to younger patients. The doctor can tell you how the figures below can be applied to your case, since the professional is familiarized with your particular situation.
The percentages below are based on the stage of cancer at the time of diagnosis. When analyzing survival rates, it is vital to understand that the stage of cancer does not change over time, even if cancer progresses. Cancer that returns or spreads is still known by the stage that was assigned when it was found and initially diagnosed, but more information is added to explain the current extent of cancer. In addition, the treatment plan is adjusted according to the change in cancer status.
The 5-year survival rate for patients with soft tissue sarcomas such as Leiomyosarcoma is around 50% on average, according to statistics from the National Cancer Institute. These statistics include patients with Kaposi’s sarcoma, which has a worse prognosis than many other sarcomas. National Cancer Institute clusters sarcomas only in case they remain confined to a primary site (localized cancer), if they have spread to nearby lymph nodes (regional cancer), or if they have spread (metastasized) to distant sites of the tumor (distant cancer). The 5-year survival rates were:
-83% for localized sarcomas (56% of soft tissue sarcomas were located at the time of diagnosis)
-54% for sarcomas in regional stage (19% were in this stage).
-16% for sarcomas with remote spread (16% were in this stage).
The 10-year relative survival rate of leiomyosarcoma is a little worse for these stages, which means that most people who survive 5 years are probably cured.
The grade and the stage are the most important predictive parameters. Small, superficial, and extremity sarcomas have a relatively low risk of recurrence, regardless of whether they are high or low grade. In larger lesions (over 5 cm) and high-grade lesions, on the other hand, the probability of recurrence is high.
In relation to the risk of local recurrence, the results of the studies suggest that the tumor grade is the most important prognostic predictive parameter. On the other hand, late recurrences seem to anticipate better from the size of the leiomyosarcoma tumor. It is estimated that after metastases are detected, the average survival time is 8 to 12 months. However, 20% to 25% of patients live 2 years after diagnosis.